John Mascarenhas

Immunotherapeutic targeting of calreticulin mutant myeloproliferative neoplasms

Abstract Calreticulin (CALR) frameshift mutations drive the majority of JAK2 / MPL -wild-type cases of essential thrombocythemia and myelofibrosis, producing a shared novel C-terminus that activates the thrombopoietin receptor and leads to constitutive Janus kinase (JAK)/signal t...